A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model

Pancreas

Volumn 41, Issue 5, 2012, Pages 789-796

  Oh, Seunguk ^a   Todhunter, Deborah A ^a   Panoskaltsis Mortari, Angela ^a   Buchsbaum, Donald J ^b   Toma, Shoko ^a   Vallera, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

EGF; Immunoconjugate therapy; Immunotoxin; Pancreatic cancer; Pseudomonas exotoxin; Xenograft model

Indexed keywords

DEGF4KDEL; EPIDERMAL GROWTH FACTOR; IMMUNOTOXIN; INTERLEUKIN 4; PSEUDOMONAS EXOTOXIN; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BIOASSAY; CANCER CELL CULTURE; CELL STRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; MUTAGENESIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; EXOTOXINS; HUMANS; IMMUNOTOXINS; INTERLEUKIN-4; LIGANDS; MALE; MICE; MICE, NUDE; MUTATION; PANCREATIC NEOPLASMS; PSEUDOMONAS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863724580     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823b5f2e     Document Type: Article

References (38)

1. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
4. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-3408.
5. Tzeng CW, Frolov A, Frolova N, et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 2007;141:464-469.
6. Lin CR, Chen WS, Kruiger W, et al. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science. 1984;224:843-848.
7. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer. 2006;94:184-188.
8. Bruell D, Bruns CJ, Yezhelyev M, et al. Recombinant anti-EGFR immunotoxin 425 (scFv)-ETA'demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med. 2005;15:305-313.
9. Bruell D, Stocker M, Huhn M, et al. The recombinant anti-EGF receptor immunotoxin 425 (scFv)-ETA'suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol. 2003;23:1179-1186.
10. Psarras K, Ueda M, Yamamura T, et al. Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas. Protein Eng. 1998;11:1285-1292.
11. Jinno H, Ueda M, Ozawa S, et al. Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines-a trial for less immunogenic chimeric toxin. Cancer Chemother Pharmacol. 1996;38:303-308.
12. Baldwin RL, Kobrin MS, Tran T, et al. Cytotoxic effects of TGF-alpha-Pseudomonas exotoxin A fusion protein in human pancreatic carcinoma cells. Pancreas. 1996;13:16-21.
13. Kornmann M, Kleeff J, Debinski W, et al. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Anticancer Res. 1999;19:125-131.
14. Kawakami K, Kawakami M, Leland P, et al. Internalization property of interleukin-4 receptor alpha chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells. Clin Cancer Res. 2002;8:258-266.
15. Friedrich K, Kammer W, Erhardt I, et al. The two subunits of the interleukin-4 receptor mediate independent and distinct patterns of ligand endocytosis. Eur J Biochem. 1999;265:457-465.
16. Jinno Y, Ogata M, Chaudhary VK, et al. Domain II mutants of Pseudomonas exotoxin deficient in translocation. J Biol Chem. 1989;264:15953-15959.
17. Nagata S, Pastan I. Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev. 2009;61:977-985.
18. Onda M, Nagata S, FitzGerald DJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol. 2006;177:8822-8834.
19. Onda M, Beers R, Xiang L, et al. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A. 2008;105:11311-11316.
20. Vallera DA, Todhunter DA, Kuroki DW, et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res. 2005;11:3879-3888.
21. Vallera DA, Todhunter D, Kuroki DW, et al. Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res. 2005;29:249-251.
22. Vallera DA, Oh S, Chen H, et al. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther. 2010;9:1872-1883.
23. Vallera DA, Shu Y, Chen H, et al. Genetically designing a more potent anti-pancreatic cancer agent by simultaneously cotargeting human IL-13 and EGF receptors in a mouse xenograft model. Gut. 2008;57:634-641.
24. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer. 1977;19:128-135.
25. Oh S, Stish BJ, Sachdev D, et al. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res. 2009;15:6137-6147.
26. Stish BJ, Oh S, Chen H, et al. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer. 2009;101:1114-1123.
27. Herrera L, Yarbrough S, Ghetie V, et al. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia. 2003;17:334-338.
28. Vartanian TK, Zamvil SS, Fox E, et al. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology. 2004;63:S42-S49.
29. Putnam WS, Prabhu S, Zheng Y, et al. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol. 2010;28:507-516.
30. Iznaga-Escobar N, Mishra AK, Perez-Rodriguez R. Factors affecting pharmacokinetics of monoclonal antibodies: a review article. Methods Find Exp Clin Pharmacol. 2004;26:123-127.
31. Powell DJ Jr, Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol. 2007;179:4919-4928.
32. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I. V. infusion to patients with mesothelin-expressing mesothelioma, ovarian and pancreatic cancers. Clin Cancer Res. 2007;13:5144-5149.
33. Garland L, Gitlitz B, Ebbinghaus S, et al. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother. 2005;28:376-381.
34. Traini R, Kreitman RJ. Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin. Bioconjug Chem. 2011;22:736-740.
35. Pai-Scherf LH, Villa J, Pearson D, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res. 1999;5(9):2311-2315.
36. Harandi A, Zaidi AS, Stocker AM, et al. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009;2009:567486 E-pub 2009 May 6.
37. Oh S, Stish BJ, Vickers SM, et al. A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. Pancreas. 2010;29:913-922.
38. Carriere D, Arcier JM, Derocq JM, et al. Antigenic modulation induced by four monoclonal antibodies adsorbed on gold particles (specificity anti-CD4, anti-CD5, anti-CD7, and anti-150-kDa antigen): relationship between modulation and cytotoxic activity of immunotoxins. Exp Cell Res. 1989;182:114-128.